Trials / Completed
CompletedNCT05119686
Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients
A Phase 2b, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of AR882 Versus Placebo in Gout Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 140 (actual)
- Sponsor
- Arthrosi Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AR882 Dose 1 | Solid Oral Capsule |
| DRUG | AR882 Dose 2 | Solid Oral Capsule |
| DRUG | Placebo | Matching Solid Oral Capsule Placebo |
Timeline
- Start date
- 2021-11-16
- Primary completion
- 2022-11-17
- Completion
- 2022-11-17
- First posted
- 2021-11-15
- Last updated
- 2023-05-12
Locations
23 sites across 3 countries: United States, Australia, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05119686. Inclusion in this directory is not an endorsement.